Clinical

Dataset Information

0

Open labeled, multicenter phase I / II study evaluating the dose escalation/ safety of Cetuximab and Oxaliplatin/ 5-FU/FA/ Irinotecan as first-line treatment of metastatic colorectal cancer


ABSTRACT: Primary ObjectiveTo assess a maximal tolerable dose of a chemotherapy-combination of Cetuximab, Irinotecan, Oxaliplatin and 5-FU/ Folinic acid as first-line treatment for metastatic colorectal cancer. Primary endpoints: To assess a maximal tolerable dose of a chemotherapy-combination of Cetuximab, Irinotecan, Oxaliplatin and 5-FU/ Folinic acid as first-line treatment for metastatic colorectal cancer.

DISEASE(S): First-line Treatment Of Metastatic Colorectal Cancer

PROVIDER: 2520357 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2036178 | ecrin-mdr-crc
| 2078718 | ecrin-mdr-crc
2022-02-17 | PXD027419 | Pride
| 2037012 | ecrin-mdr-crc
| 2515383 | ecrin-mdr-crc
2021-10-27 | GSE180790 | GEO
| 2037434 | ecrin-mdr-crc
| 2129434 | ecrin-mdr-crc
| 2063135 | ecrin-mdr-crc
| 2063032 | ecrin-mdr-crc